neuroscientist, biotech senior executive

MARK DAY, PH.D.

*/*

AREAS OF EXPERTISE

Executive Leadership Team Leadership Business Development Business Strategy & Planning Due Diligence

Contract Negotiation Statistical Analysis Risk Mitigation Strategies Research-Based Partnerships Alliance Formation Relationship Management Project Management Resource Management Corporate Restructuring

Mergers & Acquisitions M&A Financing Capital Raises Neuroscience Cognitive Neuroscience Translational Medicine Drug Discovery Proof-of-Principle PoP Proof-of-Concept PoC Research & Development R&D Research Methods Medical Affairs Scientific Affairs CNS Oncology Therapeutics Clinical Planning KOL Management Experimental Medicine Connectivity Science Target Assessment Development Pathways Grant Proposals Pipeline Management Scientific Publications Publications Planning

Data Communications Cross-Cultural Communication External Presentations Speaking Engagements Scientific Conferences Regulatory Authority Preparation OVERVIEW

• Experienced neuroscientist and executive with more than 20 years working in the biotech/pharmaceutical industry

• First and senior author publications in leading peer-reviewed journals, including Nature, Science, Nature Neuroscience, and The Proceedings of the Royal Society, among others

• Previously served on the board of directors and scientific advisory boards of multiple public and private companies

• Proven track record in external research, innovation and widely recognized for expertise and success in the evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas, including complement, oncology, and neurological/CNS diseases and disorders

• Strong track record of building alliances and executing collaborative research, business development deals, including iPierian (PSP), Prothena, Celgene, Xoma, Compass Pathways, and Rugen, among others

• Implemented and executed research strategies at multiple biotech and Fortune 500 & Fortune 100 pharmaceuticals companies, including Abbott, GSK, Alexion, BMS, Bioasis Technologies, Purdue Pharma, Otsuka U.S., and Cognito Therapeutics

• Champion/early-adopter of new, advanced discovery and research methods and platform technologies to enable new discoveries

PROFESSIONAL EXPERIENCE

Yale University, New Haven, CT 2011 – Present

Associate Professor, Translational Neuroscience (Adjunct)

• Lectures on multi-disciplinary translational approaches to drug discovery and development

• Develops experimental, pre-clinical studies in non-human primates to demonstrate translational validation in humans

• Current focus on translating neurochemical changes using in vivo imaging

• Fosters strategic alliances between Yale and the pharmaceutical / biotech industry Fairfield, CT 06824

Mobile: +1-203-***-****

**********@*****.***

Mark Day, Ph.D. Resume

2/5

Cognito Therapeutics, Inc., Cambridge, MA 2021

Chief Business Officer

• Developed strategic partnering mandate to diversify pipeline via licensing, acquisition, and partnering of clinical stage assets and commercialized products

• Refined and re-aligned near- and long-term business development strategies and guiding principles working with cross functional teams

• Led business co-development and partnership activities

• Developed and implemented proactive, targeted outreach plan as well as reactive plan, prioritizing targets in big pharma, biotech, and academic institutions

• Led big tech partnership initiatives related to wearable technologies and artificial intelligence, i.e., Apple, Google, etc.

Otsuka U.S., Princeton, NJ 2020

Vice President, Head, McQuade Centre for Research and Development & Early-Stage Life Science Investment

• Responsible for day-to-day operations of the newly formed MSRD division of Otsuka U.S.; hiring and development of MSRD team

• Streamlined global academic outreach initiative and process, prioritizing institutions based on alignment with MSRD goals and Otsuka 2030 path to growth vision

• Developed global strategic partnering mandate to diversify Otsuka pipeline via licensing, acquisition, and partnering of clinical stage assets

• Worked with global cross functional teams to developed near- and long-term business development strategies and guiding principles

• Developed and implemented proactive, targeted outreach plan as well as reactive plan, prioritizing targets in big pharma, biotech, and academic institutions

• Within first four months in position, brought in more than 125 potential business development opportunities for assessment, prioritizing by alignment with MSRD goals and Otsuka 2030 path to growth vision

• Deals executed include Compass Pathways, Rugen Therapeutics, and Eikonizo, among others Bioasis Technologies, Inc., Guilford, CT 2017 – 2019 Director, President, Chief Executive Officer, Chief Scientific Officer

• Responsible for providing cross-functional leadership across all areas of the business, including management and development of employees and consultants

• Led corporate restructuring, including formation of the company’s first scientific advisory board

• Restructured, appointed biotech-experienced board of directors and leadership team

• Hired intellectual property (IP) counsel and oversaw IP strategic development

• Focused on optimization of the xB3 platform technology enabling brain penetration of antibodies, siRNA, etc., across the blood brain barrier and to specified target sites

• Streamlined, re-focused internal R&D programs to four core programs

• Pioneered imaging study on xB3 platform technology, discovering ability to deliver trastuzumab across the Fairfield, CT 06824

Mobile: +1-203-***-****

**********@*****.***

Mark Day, Ph.D. Resume

3/5

blood brain barrier as well as the lymphatic system

• Established CRO partnerships with Wuxi Biologics, BioAgylitics, and Invicro

• Advanced pre-clinical brain metastases program to readiness for an FDA regulatory meeting

• Assumed leadership role overseeing collaborative research initiatives with the National Research Council of Canada and the Université de Sherbrooke, Texas Tech University, and Consortium de recherche biopharmaceutique (CQDM) and Brain Canada

• Redefined business development strategy for licensing of technology, securing three business development deals totaling nearly USD$40M (Prothena, Xoma, and undisclosed large U.S. pharmaceutical company)

• Rebuilt shareholder confidence in the company; implemented a long-term strategy to attract U.S. investors, which included forming a U.S. subsidiary, implementing legal and IP due diligence, and rebranding the company

• Secured New York-based investment bank to secure USD$10M bridge financing ahead of potential IPO raise

• Significantly improved external exposure and understanding of company in the U.S. through scientific discoveries and independent, through corporate, business development and investor presentations, media interviews and capitalizing on networks

Alexion Pharmaceuticals, Inc., Cheshire, CT & New Haven, CT 2015 – 2017 Executive Director, Head of External Research & Scouting

• Built out the scouting function and identified new platform technologies and potential medicines from academia, private and public companies

• Successfully completed multiple global due diligences

• Responsible for management and development of five team members Senior Director, Search and Evaluation

• Responsible for leading the search and evaluation (due diligence) processes, in-licensing, and M&A opportunities in the ultra-orphan space

• Sourced more than 100 opportunities for triage, led the due diligence activities of several functional areas for six opportunities, and presented the scientific and business case of M&A opportunities to senior management Bristol-Myers Squibb, Wallingford, CT 2012 –2014

Global Lead, CNS & Virology Business Development

• Accountable for leading search, evaluation and due diligence in the U.S. and Europe for all in-licensing and M&A interests for CNS, oncology, genetic disease, and immune-virology

• Reorganized the process for identifying top-tier opportunities, implemented an outreach program to the U.S. venture capital community, and achieved the highest business development search and evaluation statistics in two consecutive years

• Identified and ran M&A and licensing diligences on CNS, oncology, immunology, virology and genetic diseases

• Served as the Chair of the Neuroscience and GDD License Steering Committees to align business strategy

• Diligence examples included Envivo, Cytokinetics, WuXi, Tata Institute India, Acadia, among others

• Business development deals and collaborations executed include Olipass, iPerian ($700M), Santaris, among others

Fairfield, CT 06824

Mobile: +1-203-***-****

**********@*****.***

Mark Day, Ph.D. Resume

4/5

Abbott Laboratories, Lake Bluff, IL 2009 – 2012

Head of Translational Imaging and Biochemical Biomarkers

• Led the company’s identification and implementation of biomarkers to support late discovery and early development programs for all therapeutic areas

• Demonstrated improved path into proof-of-concept, changing Abbott’s stage gate requirements for entry into Phase 1

• Responsible for managing identification of 18 biomarkers to support 12 late discovery and early development programs, enabling alignment and implementation across all therapeutic areas of focus

• Reorganized the department; managed 18-member team of Ph.D.s, M.D.s, and technicians to develop translational in-house and external capabilities

• Served as chair of company’s neuroscience, osteoarthritis, and pain biomarker working groups

• Core team member for all strategy and long-range planning meetings across several sites, including San Francisco, Boston, Germany

• Identified, established, and maintained six new external collaborations and consortia to support biomarker studies across Asia, the U.S., and Europe

• Combined imaging and CSF markers into single NHP studies, and determined the full translational utility of a D3/D2 PET tracer to determine the in vivo selectivity of D3 antagonists

• Authored 18 novel publications on CNS drug activity using imaging, microdialysis, and other techniques; Edited the content of the Special Issue on Translational Medicine in Biochemical Pharmacology

• Ranked among the top-performing 10% of Abbott employees in 2009 and 2010

• Secured external collaborations to support biomarker studies, which included: o Asuragen: mRNA profiling in human CSF AMC, MCI and AD patients o Banyan Biomarkers: Effect of ABT-099 on NHP CSF and other novel biomarkers (e.g., TBI) o Invicro: Software and analytics for fMRI bone image analysis and brain atlas o Yale University: Three-year umbrella agreement for all targets o Abbott/Yale: Collaboration focused on NHP and human Phase 1 target engagement collaboration o Interivo Solutions: Aged dog CSF as a biomarker for MCI and ID o Purdue Pharma: SPECT radiotracer Tc99m to monitor anti-angionenic therapy o Maccine (five-year research agreement)

o NHP CSF as PD marker of Calpain inhibition, D3, 5HT6, a7, H3 antagonists, etc. o Novel model and analysis development of OA pain in NHPs

• Raised the internal and external profile of Abbott Imaging through corporate, business development and scientific presentations and media interviews

Wyeth Research, Princeton, NJ & Collegeville, PA 2003 – 2008 Global Lead for CNS Translational Medicine

• Led all CNS discovery and early development translational medicine programs, ensuring research was conducted within a £50 million-pound initiative

• Served as co-chair of the CNS early development team from June 2006-June 2007

• Led academic collaborations, which included: MIT & Burke Rehabilitation Center, Canadian Stroke Network, The University of Aberdeen

• Founded estrogen receptor beta CNS programs and published manuscript in Nature Neuroscience

• Transitioned nine programs into Phase 1 with biomarkers for target engagement

• Developed new congruent animal studies to predict target exposures and brain activity in humans Fairfield, CT 06824

Mobile: +1-203-***-****

**********@*****.***

Mark Day, Ph.D. Resume

5/5

• Developed an awake rat cognition fMRI behavioral procedure

• Awarded Honorary Fellow in the School of Medical Sciences at the University of Aberdeen (December 2008-2012)

• Established post-doctoral program with Canadian Stroke Network, bringing 12 new positions to Wyeth focused on improved stroke models

• Organized and chaired Winter Brain and ECNP Symposium on Translational Medicine & 2006 symposia on role of nuclear receptor hormones in Psychiatric Illness AFFILIATIONS

Society for Neuroscience, Society of Biological Psychiatry, Association of Pharmacology and Experimental Therapeutics, International Behavioral Neuroscience Society, International Society to Advance Alzheimer Research and Treatment, Parkinson’s UK Scientific Advisory Board, Scientific Advisor for BioAdvance EDUCATION

• Cardiff University, Bachelor of Science (BSc, Hons) in Biological Psychology, Cardiff, UK

• Cardiff University, Doctor of Philosophy (Ph.D.) in Neuroscience, Cardiff, UK

• The Edinburgh University, PostDoc, Senior Research Fellow in Systems Level Neuroscience, Episodic Memory and Role of NMDA and AMPA Receptors in Memory Consolidation, Edinburgh, Scotland, UK Fairfield, CT 06824

Mobile: +1-203-***-****

**********@*****.***

Contact this candidate